Acadia Pharmaceuticals isn’t taking its recent rejection from the European Medicines Agency lying down, vowing to seek a ...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of ...
A European regulatory body adopted a negative opinion regarding Acadia Pharmaceuticals' application for trofinetide, its treatment for Rett syndrome, a rare neurodevelopmental disorder seen in ...
Daybue was turned down for Rett syndrome, and Iloperidone for schizophrenia and bipolar I, with safety and benefit-risk ...
Neurogene received FDA Breakthrough Therapy Designation for NGN-401 in Rett Syndrome, driving a >25% share price surge. Click ...
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, ...
Researchers show two distinct MECP2 mutations in Rett syndrome elevate miRNA-126-3p, lowering ZO-1 and weakening blood-brain ...
Shares of Neurogene rose after the Food and Drug Administration granted breakthrough therapy designation to its NGN-401 therapy to treat Rett Syndrome. The stock jumped 36% to $26.83 in Friday's ...
A new UC Davis MIND Institute study offers critical insights into Rett syndrome, a rare genetic condition that affects mostly girls. The research reveals how this condition affects males and females ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results